Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Berkley A. Lynch, Nathalie Lambeng, Karl Nocka et al. · Proceedings of the National Academy of Sciences · 2004 · 1.6K citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series

Sonali M. Smith, Michelle M. Le Beau, Dezheng Huo et al. · Blood · 2003 · 675 citations

Medicine, Hematology, Oncology +17

Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group

Cornelia Eckert, Günter Henze, K. Seeger et al. · Journal of Clinical Oncology · 2013 · 166 citations

Medicine, Hematology, Oncology +17

Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation

Dorothy Barnard, B. Lange, Todd A. Alonzo et al. · Blood · 2002 · 80 citations

Medicine, Oncology, Pediatrics +16

Levetiracetam for busulfan‐induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation

Sandeep Soni, Micah Skeens, Amanda Termuhlen et al. · Pediatric Blood & Cancer · 2012 · 47 citations

Pharmacy, Pediatrics, Pharmacology +15